X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (159) 159
life sciences & biomedicine (129) 129
humans (87) 87
oncology (76) 76
male (63) 63
female (52) 52
middle aged (44) 44
immunotherapy (41) 41
aged (38) 38
cancer (35) 35
mutation (35) 35
lung cancer (34) 34
lung neoplasms - drug therapy (34) 34
adult (33) 33
animals (26) 26
tumors (25) 25
aged, 80 and over (24) 24
care and treatment (23) 23
carcinoma, non-small-cell lung - drug therapy (21) 21
lung neoplasms - genetics (21) 21
patients (21) 21
mice (20) 20
treatment outcome (19) 19
abridged index medicus (18) 18
chemotherapy (17) 17
lung neoplasms - pathology (17) 17
research (17) 17
analysis (16) 16
lymphocytes (16) 16
multidisciplinary sciences (16) 16
science & technology - other topics (16) 16
cell biology (15) 15
general & internal medicine (15) 15
apoptosis (14) 14
cohort studies (14) 14
medicine, general & internal (14) 14
melanoma (14) 14
respiratory system (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
carcinoma, non-small-cell lung - genetics (13) 13
health aspects (13) 13
immunology (13) 13
lung cancer, non-small cell (13) 13
antineoplastic agents - therapeutic use (12) 12
cancer therapies (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
neoplasm staging (12) 12
programmed cell death 1 receptor - antagonists & inhibitors (12) 12
biomarkers (11) 11
chemistry (10) 10
genetic aspects (10) 10
immune checkpoint (10) 10
immunotherapy - methods (10) 10
lung neoplasms - immunology (10) 10
lymphocytes t (10) 10
mice, inbred c57bl (10) 10
nivolumab (10) 10
pd-l1 protein (10) 10
prognosis (10) 10
t cells (10) 10
biochemistry & molecular biology (9) 9
disease-free survival (9) 9
ipilimumab (9) 9
metastasis (9) 9
pd-1 protein (9) 9
adenocarcinoma - drug therapy (8) 8
adenocarcinoma - genetics (8) 8
adenocarcinoma of lung (8) 8
antibodies, monoclonal - therapeutic use (8) 8
antigens (8) 8
b7-h1 antigen - antagonists & inhibitors (8) 8
carcinoma, non-small-cell lung - immunology (8) 8
hematology (8) 8
lung neoplasms - metabolism (8) 8
lung neoplasms - mortality (8) 8
non-small cell lung cancer (8) 8
original reports (8) 8
physical sciences (8) 8
survival analysis (8) 8
survival rate (8) 8
adenocarcinoma - pathology (7) 7
antibodies, monoclonal - adverse effects (7) 7
antineoplastic agents, immunological - therapeutic use (7) 7
chemistry, physical (7) 7
immune response (7) 7
immune system (7) 7
lymphocytes, tumor-infiltrating - immunology (7) 7
medical colleges (7) 7
medical research (7) 7
metastases (7) 7
neoplasms - immunology (7) 7
pd-1 (7) 7
technology (7) 7
antibodies, monoclonal - administration & dosage (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
b7-h1 antigen - immunology (6) 6
b7-h1 antigen - metabolism (6) 6
cd8-positive t-lymphocytes - immunology (6) 6
cell death (6) 6
climate change (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
Journal of investigative dermatology, ISSN 0022-202X, 09/2018, Volume 138, Issue 9, pp. 2051 - 2060
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article